Diverse mechanisms regulate the surface expression of immunotherapeutic target CTLA-4

Frontiers in Immunology

Volumn 5, Issue DEC, 2014, Pages

  Schneider, Helga ^a   Rudd, Christopher E ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

CTLA 4; LAX; Rab8; Trafficking; TRIM

Indexed keywords

ADAPTER PROTEIN 2; ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR; B7 ANTIGEN; CD86 ANTIGEN; CLATHRIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INDOLEAMINE 2, 3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 35; IPILIMUMAB; MESSENGER RNA; PHOSPHOLIPASE D; PHOSPHOPROTEIN PHOSPHATASE 2A; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN; RAP1 PROTEIN; T LYMPHOCYTE RECEPTOR; TICILIMUMAB; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CELL MIGRATION; CELLULAR IMMUNITY; COLITIS; DERMATITIS; ENDOCRINE DISEASE; EXON; HUMAN; IMMUNORECEPTOR TYROSINE BASED ACTIVATION MOTIF; KIDNEY CARCINOMA; MELANOMA; MEMORY T LYMPHOCYTE; MICROTUBULE ORGANIZING CENTER; NEOPLASM; PHASE 3 CLINICAL TRIAL (TOPIC); RECEPTOR DOWN REGULATION; REGULATORY T LYMPHOCYTE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SMALL CELL LUNG CANCER; TRANS GOLGI NETWORK;

EID: 84919767082     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00619     Document Type: Review

References (134)

1. Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP. CTLA-4-mediated inhibition of early events of T cell proliferation. J Immunol (1999) 162:5813-20.
2. Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol (2001) 19:565-94. doi: 10.1146/annurev.immunol.19.1.565
3. Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med (1996) 183:2533-40. doi:10.1084/jem.183.6.2533
4. Lee KM, Chuang E, Griffin M, Khattri R, Hong DK, Zhang W, et al. Molecular basis of T cell inactivation by CTLA-4. Science (1998) 282:2263-6. doi:10.1126/science.282.5397.2263
5. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity (1994) 1:405-13. doi:10.1016/1074-7613(94)90071-X
6. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity (1995) 3:541-7. doi:10.1016/1074-7613(95)90125-6
7. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science (1995) 270:985-8. doi:10.1126/science.270.5238.985
8. Kristiansen OP, Larsen ZM, Pociot F. CTLA-4 in autoimmune diseases - a general susceptibility gene to autoimmunity? Genes Immun (2000) 1:170-84. doi:10.1038/sj.gene.6363655
9. Liu J, Zhang H. -1722T/C polymorphism (rs733618) of CTLA-4 significantly associated with systemic lupus erythematosus (SLE): a comprehensive meta-analysis. Hum Immunol (2013) 74:341-7. doi:10.1016/j.humimm.2012.12.009
10. Pastuszak-Lewandoska D, Sewerynek E, Domanska D, Gladys A, Skrzypczak R, Brzezianska E. CTLA-4 gene polymorphisms and their influence on predisposition to autoimmune thyroid diseases (Graves' disease and Hashimoto's thyroiditis). Arch Med Sci (2012) 8:415-21. doi:10.5114/aoms.2012.28593
11. Song GG, Kim JH, Kim YH, Lee YH. Association between CTLA-4 polymorphisms and susceptibility to Celiac disease: a meta-analysis. Hum Immunol (2013) 74:1214-8. doi:10.1016/j.humimm.2013.05.014
12. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature (2003) 423:506-11. doi:10.1038/nature01621
13. Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science (2014) 345:1623-7. doi:10.1126/science.1255904
14. Callahan MK, Postow MA, Wolchok JD. Immunomodulatory therapy for melanoma: ipilimumab and beyond. Clin Dermatol (2013) 31:191-9. doi:10.1016/j.clindermatol.2012.08.006
15. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 363:711-23. doi:10.1056/NEJMoa1003466
16. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res (2013) 19:5300-9. doi:10.1158/1078-0432.CCR-13-0143
17. Brunet JF, Denizot F, Luciani M-F, Roux-Dosseto M, Suzan M-F, Mattei M-G, et al. A new member of the immunoglobulin superfamily-CTLA-4. Nature (1987) 328:267-70. doi:10.1038/328267a0
18. Ling V, Wu PW, Finnerty HF, Sharpe AH, Gray GS, Collins M. Complete sequence determination of the mouse and human CTLA4 gene loci: cross-species DNA sequence similarity beyond exon borders. Genomics (1999) 60:341-55. doi:10.1006/geno.1999.5930
19. Huurman VA, Unger WW, Koeleman BP, Oaks MK, Chandraker AK, Terpstra OT, et al. Differential inhibition of autoreactive memory- and alloreactive naive T cell responses by soluble cytotoxic T lymphocyte antigen 4 (sCTLA4), CTLA4Ig and LEA29Y. Clin Exp Immunol (2007) 150:487-93. doi:10.1111/j.1365-2249.2007.03513.x
20. Oaks MK, Hallett KM, Penwell RT, Stauber EC, Warren SJ, Tector AJ. A native soluble form of CTLA-4. Cell Immunol (2000) 201:144-53. doi:10.1006/cimm.2000.1649
21. Vijayakrishnan L, Slavik JM, Illes Z, Greenwald RJ, Rainbow D, Greve B, et al. An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells. Immunity (2004) 20:563-75. doi:10.1016/S1074-7613(04)00110-4
22. Harper K, Balzano C, Rouvier E, Mattei MG, Luziani MF, Golstein P. CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. J Immunol (1991) 147:1037-44.
23. Lindsten T, Lee KP, Harris ES, Petryniak B, Craighead N, Reynolds PJ, et al. Characterization of CTLA-4 structure and expression on human T cells. J Immunol (1993) 151:3489-99.
24. Perkins D, Wang Z, Donovan C, He H, Mark D, Guan G, et al. Regulation of CTLA-4 expression during T cell activation. J Immunol (1996) 156:4154-9.
25. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med (1991) 174:561-9. doi:10.1084/jem.174.3.561
26. Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity (1994) 1:793-801. doi:10.1016/S1074-7613(94)80021-9
27. Balzano C, Buonavista N, Rouvier E, Golstein P. CTLA-4 and CD28: similar proteins, neighbouring genes. Int J Cancer Suppl (1992) 7:28-32.
28. Schwartz JC, Zhang X, Fedorov AA, Nathenson SG, Almo SC. Structural basis for co-stimulation by the human CTLA-4/B7-2 complex. Nature (2001) 410:604-8. doi:10.1038/35069112
29. Stamper CC, Zhang Y, Tobin JF, Erbe DV, Ikemizu S, Davis SJ, et al. Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses. Nature (2001) 410:608-11. doi:10.1038/35069118
30. Chen Z, Zhou F, Huang S, Jiang T, Chen L, Ge L, et al. Association of cytotoxic T lymphocyte associated antigen-4 gene (rs60872763) polymorphism with Crohn's disease and high levels of serum sCTLA-4 in Crohn's disease. J Gastroenterol Hepatol (2011) 26:924-30. doi:10.1111/j.1440-1746.2011.06662.x
31. Liu MF, Wang CR, Chen PC, Fung LL. Increased expression of soluble cytotoxic T-lymphocyte-associated antigen-4 molecule in patients with systemic lupus erythematosus. Scand J Immunol (2003) 57:568-72. doi:10.1046/j.1365-3083.2003.01232.x
32. Oaks MK, Hallett KM. Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease. J Immunol (2000) 164:5015-8. doi:10.4049/jimmunol.164.10.5015
33. Tai X, Van Laethem F, Pobezinsky L, Guinter T, Sharrow SO, Adams A, et al. Basis of CTLA-4 function in regulatory and conventional CD4(+) T cells. Blood (2012) 119:5155-63. doi:10.1182/blood-2011-11-388918
34. Takahashi T, Kuniyasu Y, Toda M, Sakaguchi N, Itoh M, Iwata M, et al. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol (1998) 10:1969-80. doi:10.1093/intimm/10.12.1969
35. Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med (1998) 188:287-96. doi:10.1084/jem.188.2.287
36. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature (2007) 450:566-9. doi:10.1038/nature06306
37. Tadokoro CE, Shakhar G, Shen S, Ding Y, Lino AC, Maraver A, et al. Regulatory T cells inhibit stable contacts between CD4+ T cells and dendritic cells in vivo. J Exp Med (2006) 203:505-11. doi:10.1084/jem.20050783
38. Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol (2008) 9:239-44. doi:10.1038/ni1572
39. Lu Y, Schneider H, Rudd CE. Murine regulatory T cells differ from conventional T cells in resisting the CTLA-4 reversal of TCR stop-signal. Blood (2012) 120:4560-70. doi:10.1182/blood-2012-04-421420
40. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 271:1734-6. doi:10.1126/science.271.5256.1734
41. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 23:6043-53. doi:10.1200/JCO.2005.06.205
42. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A (2003) 100:4712-7. doi:10.1073/pnas.0830997100
43. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 100:8372-7. doi:10.1073/pnas.1533209100
44. Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, Millham R, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol (2005) 23:8968-77. doi:10.1200/JCO.2005.01.109
45. Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun (2013) 13:5.
46. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol (2012) 30:2691-7. doi:10.1200/JCO.2012.41.6750
47. Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med (2013) 210:1389-402. doi:10.1084/jem.20130066
48. Robert L, Tsoi J, Wang X, Emerson R, Homet B, Chodon T, et al. CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin Cancer Res (2014) 20:2424-32. doi:10.1158/1078-0432.CCR-13-2648
49. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res (2012) 18:2039-47. doi:10.1158/1078-0432.CCR-11-1823
50. Mamalis A, Garcha M, Jagdeo J. Targeting the PD-1 pathway: a promising future for the treatment of melanoma. Arch Dermatol Res (2014) 306:511-9. doi:10.1007/s00403-014-1457-7
51. Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer - preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol (2010) 37:430-9. doi:10.1053/j.seminoncol.2010.09.005
52. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev (2010) 236:219-42. doi:10.1111/j.1600-065X.2010.00923.x
53. Ise W, Kohyama M, Nutsch KM, Lee HM, Suri A, Unanue ER, et al. CTLA-4 suppresses the pathogenicity of self antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanisms. Nat Immunol (2010) 11:129-35. doi:10.1038/ni.1835
54. Bachmann MF, Kohler G, Ecabert B, Mak TW, Kopf M. Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous. J Immunol (1999) 163:1128-31.
55. Masteller EL, Chuang E, Mullen AC, Reiner SL, Thompson CB. Structural analysis of CTLA-4 function in vivo. J Immunol (2000) 164:5319-27. doi:10.4049/jimmunol.164.10.5319
56. Wang CJ, Kenefeck R, Wardzinski L, Attridge K, Manzotti C, Schmidt EM, et al. Cutting edge: cell-extrinsic immune regulation by CTLA-4 expressed on conventional T cells. J Immunol (2012) 189:1118-22. doi:10.4049/jimmunol.1200972
57. Chuang E, Fisher TS, Morgan RW, Robbins MD, Duerr JM, Vander Heiden MG, et al. The CD28 and CTLA-4 receptors associate with the serine/threonine phosphatase PP2A. Immunity (2000) 13:313-22. doi:10.1016/S1074-7613(00)00031-5
58. Schneider H, Smith X, Liu H, Bismuth G, Rudd CE. CTLA-4 disrupts ZAP70 microcluster formation with reduced T cell/APC dwell times and calcium mobilization. Eur J Immunol (2008) 38:40-7. doi:10.1002/eji.200737423
59. Pentcheva-Hoang T, Egen JG, Wojnoonski K, Allison JP. B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity (2004) 21:401-13. doi:10.1016/j.immuni.2004.06.017
60. Chikuma S, Imboden JB, Bluestone JA. Negative regulation of T cell receptor-lipid raft interaction by cytotoxic T lymphocyte-associated antigen 4. J Exp Med (2003) 197:129-35. doi:10.1084/jem.20021646
61. Darlington PJ, Baroja ML, Chau TA, Siu E, Ling V, Carreno BM, et al. Surface cytotoxic T lymphocyte-associated antigen 4 partitions within lipid rafts and relocates to the immunological synapse under conditions of inhibition of T cell activation. J Exp Med (2002) 195:1337-47. doi:10.1084/jem.20011868
62. Martin M, Schneider H, Azouz A, Rudd CE. Cytotoxic T lymphocyte antigen 4 potently inhibits cell surface raft expression in its regulation of T cell function. J Exp Med (2001) 194:1675-81. doi:10.1084/jem.194.11.1675
63. Rudd CE, Martin M, Schneider H. CTLA-4 negative signaling via lipid rafts: a new perspective. Sci STKE (2002) 2002:E18.
64. Rudd CE, Schneider H. Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling. Nat Rev Immunol (2003) 3:544-56. doi:10.1038/nri1131
65. Schneider H, Prasad KVS, Shoelson SE, Rudd CE. CTLA-4 binding to the lipid kinase phosphatidylinositol 3-kinase in T cells. J Exp Med (1995) 181:351-5. doi:10.1084/jem.181.1.351
66. Cilio CM, Daws MR, Malashicheva A, Sentman CL, Holmberg D. Cytotoxic T lymphocyte antigen 4 is induced in the thymus upon in vivo activation and its blockade prevents anti-CD3-mediated depletion of thymocytes. J Exp Med (1998) 188:1239-46. doi:10.1084/jem.188.7.1239
67. Marengère LEM, Waterhouse P, Duncan GS, Mittrücker H-W, Feng G-S, Mak TW. Regulation of T cell receptor signaling by tyrosine phosphatase Syp association with CTLA-4. Science (1996) 272:1170-3. doi:10.1126/science.272.5265.1170
68. Chuang E, Alegre M-L, Duckett CS, Noel PJ, Vander Heiden MG, Thompson CB. Interaction of CTLA-4 with the clathrin-associated protein AP50 results in ligand-independent endocytosis that limits cell surface expression. J Immunol (1997) 159:144-51.
69. Schneider H, Martin M, Agarraberes FA, Yin L, Rapoport I, Kirchhausen T, et al. Cytolytic T lymphocyte-associated antigen-4 and the TcRz/CD3 complex, but not CD28, interact with clathrin adaptor complexes AP-1 and AP-2. J Immunol (1999) 163:1868-79.
70. Zhang Y, Allison JP. Interaction of CTLA-4 with AP-50, a clathrin-coated pit adaptor protein. Proc Natl Acad Sci U S A (1997) 94:9273-8. doi:10.1073/pnas.94.17.9273
71. Teft WA, Chau TA, Madrenas J. Structure-function analysis of the CTLA-4 interaction with PP2A. BMC Immunol (2009) 10:23. doi:10.1186/1471-2172-10-23
72. Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol (2005) 25:9543-53. doi:10.1128/MCB.25.21.9543-9553.2005
73. Boasso A, Herbeuval JP, Hardy AW, Winkler C, Shearer GM. Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells. Blood (2005) 105:1574-81. doi:10.1182/blood-2004-06-2089
74. Fallarino F, Grohmann U, Hwang KW, Orabona C, Vacca C, Bianchi R, et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol (2003) 4:1206-12. doi:10.1038/ni1003
75. Munn DH, Mellor AL. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol (2013) 34:137-43. doi:10.1016/j.it.2012.10.001
76. Schmidt SV, Schultze JL. New insights into IDO biology in bacterial and viral infections. Front Immunol (2014) 5:384. doi:10.3389/fimmu.2014.00384
77. Mellor AL, Munn D, Chandler P, Keskin D, Johnson T, Marshall B, et al. Tryptophan catabolism and T cell responses. Adv Exp Med Biol (2003) 527:27-35. doi:10.1007/978-1-4615-0135-0_3
78. Oida T, Xu L, Weiner HL, Kitani A, Strober W. TGF-beta-mediated suppression by CD4+CD25+ T cells is facilitated by CTLA-4 signaling. J Immunol (2006) 177:2331-9. doi:10.4049/jimmunol.177.4.2331
79. Sullivan TJ, Letterio JJ, van Elsas A, Mamura M, van Amelsfort J, Sharpe S, et al. Lack of a role for transforming growth factor-b in cytotoxic T lymphocyte antigen-4-mediated inhibition of T cell activation. Proc Natl Acad Sci USA (2001) 98:2587-92. doi:10.1073/pnas.051632398
80. Letterio JJ, Geiser AG, Kulkarni AB, Dang H, Kong L, Nakabayashi T, et al. Autoimmunity associated with TGF-beta1-deficiency in mice is dependent on MHC class II antigen expression. J Clin Invest (1996) 98:2109-19. doi:10.1172/JCI119017
81. Ramsdell F, Ziegler SF. FOXP3 and scurfy: how it all began. Nat Rev Immunol (2014) 14:343-9. doi:10.1038/nri3650
82. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science (2008) 322:271-5. doi:10.1126/science.1160062
83. Wing K, Yamaguchi T, Sakaguchi S. Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation. Trends Immunol (2011) 32:428-33. doi:10.1016/j.it.2011.06.002
84. Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science (2011) 332:600-3. doi:10.1126/science.1202947
85. Kong KF, Fu G, Zhang Y, Yokosuka T, Casas J, Canonigo-Balancio AJ, et al. Protein kinase C-n controls CTLA-4-mediated regulatory T cell function. Nat Immunol (2014) 15:465-72. doi:10.1038/ni.2866
86. Yokosuka T, Kobayashi W, Takamatsu M, Sakata-Sogawa K, Zeng H, Hashimoto-Tane A, et al. Spatiotemporal basis of CTLA-4 costimulatory molecule-mediated negative regulation of T cell activation. Immunity (2010) 33:326-39. doi:10.1016/j.immuni.2010.09.006
87. Rudd CE. The reverse stop-signal model for CTLA4 function. Nat Rev Immunol (2008) 8:153-60. doi:10.1038/nri2253
88. Schneider H, Downey J, Smith A, Zinselmeyer BH, Rush C, Brewer JM, et al. Reversal of the TCR stop signal by CTLA-4. Science (2006) 313:1972-5. doi:10.1126/science.1131078
89. Dillon TJ, Carey KD, Wetzel SA, Parker DC, Stork PJ. Regulation of the small GTPase Rap1 and extracellular signal-regulated kinases by the costimulatory molecule CTLA-4. Mol Cell Biol (2005) 25:4117-28. doi:10.1128/MCB.25.10.4117-4128.2005
90. Schneider H, Valk E, Dias S, Wei B, Rudd CE. CTLA-4 up-regulation of lymphocyte function-associated antigen 1 adhesion and clustering as an alternate basis for coreceptor function. Proc Natl Acad Sci U S A (2005) 102:12861-6. doi:10.1073/pnas.0505802102
91. Hara S, Nakaseko C, Yamasaki S, Hattori M, Bos JL, Saito Y, et al. Involvement of Rap-1 activation and early termination of immune synapse in CTLA-4-mediated negative signal. Hematology (2009) 14:150-8. doi:10.1179/102453309X402241
92. Knieke K, HoffH, Maszyna F, Kolar P, Schrage A, Hamann A, et al. CD152 (CTLA-4) determines CD4 T cell migration in vitro and in vivo. PLoS One (2009) 4:e5702. doi:10.1371/journal.pone.0005702
93. Mustelin T. Immunology. Restless T cells sniffand go. Science (2006) 313:1902-3. doi:10.1126/science.1133578
94. Ruocco MG, Pilones KA, Kawashima N, Cammer M, Huang J, Babb JS, et al. Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. J Clin Invest (2012) 122:3718-30. doi:10.1172/JCI61931
95. Lozanoska-Ochser B, Klein NJ, Huang GC, Alvarez RA, Peakman M. Expression of CD86 on human islet endothelial cells facilitates T cell adhesion and migration. J Immunol (2008) 181:6109-16. doi:10.4049/jimmunol.181.9.6109
96. Linsley PS, Bradshaw J, Greene J, Peach R, Bennet KL, Mittler RS. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity (1996) 4:535-43. doi:10.1016/S1074-7613(00)80480-X
97. Mead KI, Zheng Y, Manzotti CN, Perry LC, Liu MK, Burke F, et al. Exocytosis of CTLA-4 is dependent on phospholipase D and ADP ribosylation factor-1 and stimulated during activation of regulatory T cells. J Immunol (2005) 174:4803-11. doi:10.4049/jimmunol.174.8.4803
98. Blumberg RS, Ley S, Sancho J, Lonberg N, Lacy E, McDermott F, et al. Structure of the T-cell antigen receptor: evidence for two CD3 epsilon subunits in the T-cell receptor-CD3 complex. Proc Natl Acad Sci U S A (1990) 87:7220-4. doi:10.1073/pnas.87.18.7220
99. Rutledge T, Cosson P, Manolios N, Bonifacino JS, Klausner RD. Transmembrane helical interactions: zeta chain dimerization and functional association with the T cell antigen receptor. EMBO J (1992) 11:3245-54.
100. Kliche S, Lindquist JA, Schraven B. Transmembrane adapters: structure, biochemistry and biology. Semin Immunol (2004) 16:367-77. doi:10.1016/j.smim.2004.08.017
101. Lindquist JA, Simeoni L, Schraven B. Transmembrane adapters: attractants for cytoplasmic effectors. Immunol Rev (2003) 191:165-82. doi:10.1034/j.1600-065X.2003.00007.x
102. Bruyns E, Marie-Cardine A, Kirchgessner H, Sagolla K, Shevchenko A, Mann M, et al. T cell receptor (TCR) interacting molecule (TRIM), a novel disulfide-linked dimer associated with the TCR-CD3-zeta complex, recruits intracellular signaling proteins to the plasma membrane. J Exp Med (1998) 188:561-75. doi:10.1084/jem.188.3.561
103. Zhu M, Granillo O, Wen R, Yang K, Dai X, Wang D, et al. Negative regulation of lymphocyte activation by the adaptor protein LAX. J Immunol (2005) 174:5612-9. doi:10.4049/jimmunol.174.9.5612
104. Kölsch U, Arndt B, Reinhold D, Lindquist JA, Juling N, Kliche S, et al. Normal T-cell development and immune functions in TRIM-deficient mice. Mol Cell Biol (2006) 26:3639-48. doi:10.1128/MCB.26.9.3639-3648.2006
105. Kirchgessner H, Dietrich J, Scherer J, Isomaki P, Korinek V, Hilgert I, et al. The transmembrane adaptor protein TRIM regulates T cell receptor (TCR) expression and TCR-mediated signaling via an association with the TCR zeta chain. J Exp Med (2001) 193:1269-84. doi:10.1084/jem.193.11.1269
106. Shapiro MJ, Nguyen CT, Aghajanian H, Zhang W, Shapiro VS. Negative regulation of TCR signaling by linker for activation of X cells via phosphotyrosine-dependent and -independent mechanisms. J Immunol (2008) 181:7055-61. doi:10.4049/jimmunol.181.10.7055
107. Zhu M, Janssen E, Leung K, Zhang W. Molecular cloning of a novel gene encoding a membrane-associated adaptor protein (LAX) in lymphocyte signaling. J Biol Chem (2002) 277:46151-8. doi:10.1074/jbc. M208946200
108. Valk E, Leung R, Kang H, Kaneko K, Rudd CE, Schneider H. T cell receptor-interacting molecule acts as a chaperone to modulate surface expression of the CTLA-4 coreceptor. Immunity (2006) 25:807-21. doi:10.1016/j.immuni.2006.08.024
109. Valk E, Rudd CE, Schneider H. CTLA-4 trafficking and surface expression. Trends Immunol (2008) 29:272-9. doi:10.1016/j.it.2008.02.011
110. Banton MC, Inder KL, Valk E, Rudd CE, Schneider H. Rab8 binding to immune cell-specific adaptor LAX facilitates formation of trans-Golgi network-proximal CTLA-4 vesicles for surface expression. Mol Cell Biol (2014) 34:1486-99. doi:10.1128/MCB.01331-13
111. Dietrich J, Kastrup J, Lauritsen JP, Menne C, von Bulow F, Geisler C. TCRzeta is transported to and retained in the Golgi apparatus independently of other TCR chains: implications for TCR assembly. Eur J Immunol (1999) 29:1719-28. doi:10.1002/(SICI)1521-4141(199905)29:05<1719::AID-IMMU1719>3.3.CO;2-D
112. Pfeffer S, Aivazian D. Targeting Rab GTPases to distinct membrane compartments. Nat Rev Mol Cell Biol (2004) 5:886-96. doi:10.1038/nrm1500
113. Stenmark H. Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell Biol (2009) 10:513-25. doi:10.1038/nrm2728
114. Zerial M, McBride H. Rab proteins as membrane organizers. Nat Rev Mol Cell Biol (2001) 2:107-17. doi:10.1038/35052055
115. Peränen J, Auvinen P, Virta H, Wepf R, Simons K. Rab8 promotes polarized membrane transport through reorganization of actin and microtubules in fibroblasts. J Cell Biol (1996) 135:153-67. doi:10.1083/jcb.135.1.153
116. Peränen J, Furuhjelm J. Expression, purification, and properties of Rab8 function in actin cortical skeleton organization and polarized transport. Methods Enzymol (2001) 329:188-96. doi:10.1016/S0076-6879(01)29079-X
117. Hattula K, Furuhjelm J, Tikkanen J, Tanhuanpaa K, Laakkonen P, Peränen J. Characterization of the Rab8-specific membrane traffic route linked to protrusion formation. J Cell Sci (2006) 119:4866-77. doi:10.1242/jcs.03275
118. Nagabhushana A, Chalasani ML, Jain N, Radha V, Rangaraj N, Balasubramanian D, et al. Regulation of endocytic trafficking of transferrin receptor by optineurin and its impairment by a glaucoma-associated mutant. BMC Cell Biol (2010) 11:4. doi:10.1186/1471-2121-11-4
119. Dong C, Yang L, Zhang X, Gu H, Lam ML, Claycomb WC, et al. Rab8 interacts with distinct motifs in alpha2B- and beta2-adrenergic receptors and differentially modulates their transport. J Biol Chem (2010) 285:20369-80. doi:10.1074/jbc. M109.081521
120. Beraud-Dufour S, Balch W. A journey through the exocytic pathway. J Cell Sci (2002) 115:1779-80.
121. D'Souza-Schorey C, Chavrier P. ARF proteins: roles in membrane traffic and beyond. Nat Rev Mol Cell Biol (2006) 7:347-58. doi:10.1038/nrm1910
122. Freyberg Z, Siddhanta A, Shields D. "Slip, sliding away": phospholipase D and the Golgi apparatus. Trends Cell Biol (2003) 13:540-6. doi:10.1016/j.tcb.2003.08.004
123. Carrasco S, Merida I. Diacylglycerol, when simplicity becomes complex. Trends Biochem Sci (2007) 32:27-36. doi:10.1016/j.tibs.2006.11.004
124. Shemesh T, Luini A, Malhotra V, Burger KN, Kozlov MM. Prefission constriction of Golgi tubular carriers driven by local lipid metabolism: a theoretical model. Biophys J (2003) 85:3813-27. doi:10.1016/S0006-3495(03)74796-1
125. Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med (2000) 192:303-10. doi:10.1084/jem.192.2.303
126. Bradshaw JD, Lu P, Leytze G, Rodgers J, Schieven GL, Bennett KL, et al. Interaction of the cytoplasmic tail of CTLA-4 (CD152) with a clathrin-associated protein is negatively regulated by tyrosine phosphorylation. Biochemistry (1997) 36:15975-82. doi:10.1021/bi971762i
127. Shiratori T, Miyatake S, Ohno H, Nakaseko C, Isono K, Bonifacino JS, et al. Tyrosine phosphorylation controls internalization of CTLA-4 by regulating its interaction with clathrin-associated adaptor complex AP-2. Immunity (1997) 6:583-9. doi:10.1016/S1074-7613(00)80346-5
128. Miyatake S, Nakaseko C, Umemori H, Yamamoto T, Saito T. Src family tyrosine kinases associate with and phosphorylate CTLA-4 (CD 152). Biochem Biophys Res Commun (1998) 249:444-8. doi:10.1006/bbrc.1998.9191
129. Schneider H, Schwartzberg PL, Rudd CE. Resting lymphocyte kinase (Rlk/Txx) phosphorylates the YVKM motif and regulates PI 3-kinase binding to T-cell antigen CTLA-4. Biochem Biophys Res Commun (1998) 252:14-9. doi:10.1006/bbrc.1998.9559
130. Guntermann C, Alexander DR. CTLA-4 suppresses proximal TCR signaling in resting human CD4(+) T cells by inhibiting ZAP-70 Tyr(319) phosphorylation: a potential role for tyrosine phosphatases. J Immunol (2002) 168:4420-9. doi:10.4049/jimmunol.168.9.4420
131. Kozik P, Francis RW, Seaman MN, Robinson MS. A screen for endocytic motifs. Traffic (2010) 11:843-55. doi:10.1111/j.1600-0854.2010.01056.x
132. Iida T, Ohno H, Nakaseko C, Sakuma M, Takeda-Ezaki M, Arase H, et al. Regulation of cell surface expression of CTLA-4 by secretion of CTLA-4-containing lysosomes upon activation of CD4+ T cells. J Immunol (2000) 165:5062-8. doi:10.4049/jimmunol.165.9.5062
133. Egen JG, Allison JP. Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity (2002) 16:23-35. doi:10.1016/S1074-7613(01)00259-X
134. Jago CB, Yates J, Camara NO, Lechler RI, Lombardi G. Differential expression of CTLA-4 among T cell subsets. Clin Exp Immunol (2004) 136:463-71. doi:10.1111/j.1365-2249.2004.02478.x